SG/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.09.24 | Real-time Boerse Frankfurt Warrants 08:00:25 07/06/2024 BST | ||
| 2.38 EUR | -2.46% |
|
| Current month | +84.85% | ||
| 1 month | +454.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 2.38 | -2.46% |
| 06/06/24 | 2.44 | 0.00% |
| 05/06/24 | 2.44 | +19.61% |
| 04/06/24 | 2.04 | +19.30% |
| 03/06/24 | 1.71 | +29.55% |
Real-time Boerse Frankfurt Warrants
Last update June 07, 2024 at 08:00 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6C4A |
| ISIN | DE000SU6C4A8 |
| Date issued | 28/12/2023 |
| Strike | 500 $ |
| Maturity | 20/09/2024 (106 Days) |
| Parity | 10 : 1 |
| Emission price | 1.49 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.55 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.2 € |
| Spread % | 7.75% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
485.5
USD
Average target price
463.5
USD
Spread / Average Target
-4.53%
- Stock Market
- Warrants
- Warrant